Roivant Sciences Ltd.

NasdaqGS ROIV

Roivant Sciences Ltd. Return on Equity (ROE) for the year ending March 31, 2024: 72.86%

Roivant Sciences Ltd. Return on Equity (ROE) is 72.86% for the year ending March 31, 2024, a 0.00% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Roivant Sciences Ltd. Return on Equity (ROE) for the year ending March 31, 2024 was 72.86%, a 183.60% change year over year.
Roivant Sciences Ltd. Return on Equity (ROE) for the year ending March 31, 2023 was -87.15%, a -70.84% change year over year.
Roivant Sciences Ltd. Return on Equity (ROE) for the year ending March 31, 2022 was -51.01%, a -13.33% change year over year.
Roivant Sciences Ltd. Return on Equity (ROE) for the year ending March 31, 2021 was -45.01%, a -176.20% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGS: ROIV

Roivant Sciences Ltd.

CEO	Mr. Matthew Gline
IPO Date	Dec. 8, 2020
Location	United Kingdom
Headquarters	11-12 St. James's Square
Employees	908
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Vaccines

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Key trends

Past 5 years